Engaging the power of the bodyâs own immune system in combination with Agilvaxâs proprietary Virus Like Particle (VLP) platform technology, Agilvax is able rapidly to identify and select lead immunotherapy candidates. The firm optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. Immunotherapies with demonstrated clinical effectiveness are brought forward through pre-clinical and clinical testing. This process results in the development of effective and robust immunotherapies and vaccines that represent attractive out-licensing opportunities for Pharmaceutical and (or) Biotechnology partners. Agilvax's lead asset is AX09 immunotherapy candidate for the treatment of aggressive forms of breast cancer. Immunization with AX09 elicits antibodies targeting breast cancer stem cells, a key cellular reservoir for relapse, metastatic progression and therapeutic resistanc
